Opportunities and challenges of multidisciplinary conversion therapy in advanced hepatocellular carcinoma
Main Article Content
Abstract
Surgical resection is still the most important radical treatment for primary hepatocellular carcinoma (HCC), but at present, the resection rate of newly diagnosed patients with HCC is only 30%. The recurrence rate of newly diagnosed patients suitable for surgical resection within 5 years after surgery is as high as 40%~70%. Low initial resection rate and high postoperative recurrence rate are important reasons restricting the overall treatment effects of HCC in China. Under this background, effectively improving the resection rate of HCC and reducing the postoperative recurrence rate have become the key topics to improve the treatment effects of HCC. Some initially unresectable HCC patients may have access to surgery through conversion therapy. Conversion therapy, which mainly involves the combination of local, systemic, and multiple treatment strategies, offers hope for patients with advanced HCC. But there are still some patients who do not benefit from conversion therapy. So, how to improve the conversion success rate is still one of the challenges that clinicians need to solve.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
- Zuo M, Zheng G, Cao Y, et al. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high-risk: A propensity score matching study. International Journal of Surgery. Published online July 12, 2024. https://doi.org/10.1097/js9.0000000000001940
- Lin YD, Wu GS, Rao MY, et al. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial. Scientific Reports. 2024, 14(1). https://doi.org/10.1038/s41598-024-62523-z
- Tada T, Kumada T, Hiraoka A, et al. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. Alimentary Pharmacology & Therapeutics. 2024, 60(2): 233-245. https://doi.org/10.1111/apt.18037
- Melero I, Yau T, Kang YK, et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Annals of Oncology. 2024, 35(6): 537-548. https://doi.org/10.1016/j.annonc.2024.03.005
- Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. The Lancet Gastroenterology & Hepatology. 2023, 8(2): 169-178. https://doi.org/10.1016/s2468-1253(22)00339-9
- Liu D, Mu H, Liu C, et al. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. Neoplasma. 2024, 70(06): 811-818. https://doi.org/10.4149/neo_2023_230806n413
- Zhang W, Tong S, Hu B, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. Journal for ImmunoTherapy of Cancer. 2023, 11(9): e007366. https://doi.org/10.1136/jitc-2023-007366
- Li J, Kong M, Yu G, et al. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. Frontiers in Immunology. 2023, 14. https://doi.org/10.3389/fimmu.2023.1188308
- Chen B, Huang B. Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab. Liver International. 2024, 44(7): 1735-1735. https://doi.org/10.1111/liv.15944
- Zhang Y, Ma Y, Wang E, et al. Conversion therapy for advanced biphenotypic hepatocellular carcinoma: A case report. Asian Journal of Surgery. Published online July 2024. https://doi.org/10.1016/j.asjsur.2024.07.016
- Wu J long, Peng P, Hu Z min, et al. A case of conversion therapy for hepatocellular carcinoma with bile-duct tumor thrombus. Asian Journal of Surgery. 2024, 47(8): 3688-3689. https://doi.org/10.1016/j.asjsur.2024.04.039
- Yau T, Zagonel V, Santoro A, et al. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology. Published online December 13, 2022. https://doi.org/10.1200/jco.22.00972
- Chen S, Shi F, Wu Z, et al. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma. 2023, 10: 1209-1222. https://doi.org/10.2147/jhc.s417550
- Liu R, Qian MP, Cui YY. Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma. Metabolism. 2023, 147: 155665. https://doi.org/10.1016/j.metabol.2023.155665
- Zhu XD, Huang C, Shen YH, et al. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer. 2021, 10(4): 320-329. https://doi.org/10.1159/000514313
- LIN ZP, HU XL, CHEN D, et al. Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma. Journal of Physiology & Pharmacology, 2022, 73(6).
- Zhang J, Zhang X, Mu H, et al. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Frontiers in Oncology. 2021, 11. https://doi.org/10.3389/fonc.2021.729764
- Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology. 2020, 38(26): 2960-2970. https://doi.org/10.1200/jco.20.00808
- Song WJ, Xu J, Nie Y, et al. Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus: A case report and review of literature. World Journal of Clinical Cases. 2024, 12(16): 2847-2855. https://doi.org/10.12998/wjcc.v12.i16.2847
- Zhao W, Liu C, Wu Y, et al. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. Translational Cancer Research. 2024, 13(5): 2315-2331. https://doi.org/10.21037/tcr-24-93
- Shimose S, Saeki I, Tomonari T, et al. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice. Oncology Letters. 2024, 28(2). https://doi.org/10.3892/ol.2024.14530
- Sangro B, Galle PR, Kelley RK, et al. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology. 2024, 42(23): 2790-2799. https://doi.org/10.1200/jco.23.01462
- Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Annals of Oncology. 2024, 35(5): 448-457. https://doi.org/10.1016/j.annonc.2024.02.005
- Wang M, Xu X, Wang K, et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science. 2024, 115(7): 2159-2169. https://doi.org/10.1111/cas.16194
- Li X, Chen J, Wang X, et al. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors. Frontiers in Oncology. 2023, 13. https://doi.org/10.3389/fonc.2023.1110689
- Guo B, Zhou Y, Liu Z, et al. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report. Clinics and Research in Hepatology and Gastroenterology. 2023, 47(7): 102169. https://doi.org/10.1016/j.clinre.2023.102169
- Pang B, Zuo B, Huang L, et al. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. International Immunopharmacology. 2024, 137: 112492. https://doi.org/10.1016/j.intimp.2024.112492
- Tang Z, Bai T, Wei T, et al. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study. BMC Cancer. 2024, 24(1). https://doi.org/10.1186/s12885-024-12484-3
- He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. JAMA Oncology. 2019, 5(7): 953. https://doi.org/10.1001/jamaoncol.2019.0250
- Chang X, Li X, Sun P, et al. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study. BMC Cancer. 2024, 24(1). https://doi.org/10.1186/s12885-024-12233-6
- Liu J, Li Z, Zhang W, et al. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Frontiers in Pharmacology. 2021, 12. https://doi.org/10.3389/fphar.2021.709060
- Jiang X, Aljbri A, Liu J, et al. Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report. Frontiers in Oncology. 2024, 14. https://doi.org/10.3389/fonc.2024.1401882
- Liang C, He Z, Tao Q, et al. From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies. Journal of Clinical Medicine. 2023, 12(24): 7665. https://doi.org/10.3390/jcm12247665
- Sato S, Aoki T, Matsumoto T, et al. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review. Clinical Journal of Gastroenterology. 2023, 17(2): 292-299. https://doi.org/10.1007/s12328-023-01895-7
- Takamoto T, Maruki Y, Kondo S. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma. Expert Opinion on Pharmacotherapy. 2023, 24(14): 1567-1575. https://doi.org/10.1080/14656566.2023.2229728
- Chu JH, Huang LY, Wang YR, et al. Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature. World Journal of Gastrointestinal Oncology. 2024, 16(4): 1647-1659. https://doi.org/10.4251/wjgo.v16.i4.1647